Arcitumomab is a drug used for diagnosis in cancer medicine. Approximately 95 percent of all colorectal cancers can be diagnosed by intravenous administration of arcitumomab in an imaging procedure. This approach is necessary in part because colorectal cancer is usually very difficult to diagnose in any other way. This is because this type of cancer … Arcitumomab: Effects, Uses & Risks
Colorectal cancer does not occur overnight. But the first signs are uncharacteristic and there is no pain, so the symptoms are easily dismissed as a condition and early-stage colorectal cancer is often discovered only by chance. The fact that there are no reliable early symptoms of colorectal cancer makes early detection all the more significant. … Colorectal Cancer: Common Signs
Malignant colorectal tumors occupy an inglorious top position in industrialized countries: They rank third among cancers in both men and women. In 2018, 1.8 million people worldwide had colorectal cancer. Almost all malignant neoplasms originate from the glandular tissue of the mucosa of the colon (adenocarcinoma); cancer of the small intestine is very rare. Where … Colorectal Cancer
Colorectal cancer is a disease that for a long time, and even today, has been associated with many misconceptions and false embarrassment. Many people still do not know that colorectal cancer is preventable through screening and do not go for screening based on this misconception. Others avoid screening because they assume they will inevitably die … 8 Myths Surrounding Colorectal Cancer
Colorectal cancer is the second most common cancer – about 70,000 cases are diagnosed annually in Germany. It occurs more frequently after the age of 45. However, people who carry a hereditary risk often develop the disease at a much younger age. Often asymptomatic for years Colorectal cancer is a “silent killer” – for many … Colorectal Cancer: Risk Factors
Products Cetuximab is commercially available as an infusion solution (Erbitux). It has been approved in many countries since 2003. Structure and properties Cetuximab is a recombinant chimeric (human/mouse) IgG1 monoclonal antibody. It is produced by biotechnological methods. Effects Cetuximab (ATC L01XC06) has antitumor and antiangiogenic properties. It is a specific antibody against the epidermal growth … Cetuximab
The drug afatinib is a relatively new agent used in the treatment of lung cancer. It works against cancer by blocking growth factors in cells. What is afatinib? Lung cancer-affected alveoli (alveoli) labeled in section. Click to enlarge. The drug afatinib is used to treat adult patients suffering from advanced-stage non-small cell lung cancer. It … Afatinib: Effects, Uses & Risks
Products Regorafenib is commercially available in the form of film-coated tablets (Stivarga). It was approved in many countries in February 2013. Structure and properties Regorafenib (C21H15ClF4N4O3, Mr = 482.8 g/mol) is present in drugs as regorafenib monohydrate, which is practically insoluble in water. Effects Regorafenib (ATC L01XE21) has antitumor and antiangiogenic properties. The effects are … Regorafenib
In the following you will find a list and short description of the most important diseases of the gastrointestinal tract. For further information, you will find a reference to the main article on the respective disease at the end of each section. In the following you will find the most common diseases of the gastrointestinal … Diseases of the gastrointestinal tract
Other diseases of the gastrointestinal tract The peritoneum lines the abdominal cavity from the inside and thus has contact with the abdominal organs from the outside. Peritonitis is a serious disease that should be treated as an in-patient as it can be fatal. It occurs when pathogens of the gastrointestinal tract leave the tract and … Other diseases of the gastrointestinal tract | Diseases of the gastrointestinal tract
Products Panitumumab is commercially available as an infusion solution (Vectibix). It has been approved in many countries since 2008. Structure and properties Panitumumab is a recombinant, fully human IgG2 monoclonal antibody against EGFR. Effects Panitumumab (ATC L01XC08) has antitumor and antiangiogenic properties. The effects are due to binding to the epidermal growth factor receptor (EGFR). … Panitumumab
Introduction Colon cancer is the second most common cancer in women and the third most common cancer in men. Like most other types of cancer, colorectal cancer is divided into different stages. This is done according to the so-called TNM classification. The course of the disease depends largely on which tumour stage is involved. While … The course of colon cancer
